| EMR |
Report |
Adjusted EPS |
BEAT |
pred ~$1.71 vs. cons $1.68 |
MEDIUM |
| EMR |
Report |
Net sales |
IN-LINE |
pred ~$4.82B vs. cons $4.80B |
MEDIUM |
| EMR |
Report |
Underlying orders growth |
BEAT |
pred ~5.5% vs. cons 5.0% |
MEDIUM |
| EMR |
Guide |
Adjusted EPS |
BETTER |
guide ~$6.55 midpoint vs. cons $6.49 (FY2026) |
MEDIUM |
| EMR |
Guide |
Adjusted EPS |
BETTER |
guide ~$1.84 midpoint vs. cons $1.81 (Q4 FY2026) |
LOW |
| EMR |
Guide |
Underlying sales growth |
UNCHANGED |
guide ~3.0% vs. cons 3.0% (FY2026) |
MEDIUM |
| EMR |
Guide |
Free cash flow |
UNCHANGED |
guide ~$3.55B midpoint vs. cons $3.55B (FY2026) |
MEDIUM |
| EMR |
Return |
Day-1 residual (stock − beta × S&P 500) |
+1.8% |
— |
MEDIUM |
| EMR |
Return |
5-day cumulative residual |
+0.8% (FADE) |
The initial reaction benefits from predicted EPS of ~$1.71 versus $1.68 consensus and a FY2026 guide midpoint of ~$6.55 versus $6.49 consensus, but the implied Q4 outlook of ~$1.84 versus $1.81 provides only modest out-period estimate upside; the pre-earnings rally and elevated valuation should limit follow-through. |
MEDIUM |